Maximum quantity allowed is 999
请选择数量
CAS RN: 58-32-2 | 產品號碼: D2274
補充產品訊息:
This product is a sample for RUO (research use only). Do not use this product for any purpose other than testing and research.
| 產品號碼 | D2274 |
| 純度/分析方法 | >98.0%(T)(HPLC) |
| 分子式 / 分子量 | C__2__4H__4__0N__8O__4 = 504.64 |
| 外觀與形狀（20°C） | Solid |
| 儲存條件 | Room Temperature (Recommended in a cool and dark place, <15°C) |
| 應避免的情況 | Light Sensitive |
| CAS RN | 58-32-2 |
| Reaxys-RN | 68373 |
| PubChem Substance ID | 87568711 |
| SDBS (AIST Spectral DB) | 19363 |
| Merck Index(14) | 3346 |
| MDL編號 | MFCD00010555 |
產品規格
| Appearance | Light yellow to Yellow to Orange powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Nonaqueous Titration) | min. 98.0 % |
| NMR | confirm to structure |
性質
| 熔點 | 168 °C |
| 溶解性（可溶於） | Chloroform |
GHS
| 圖形表示 |
|
| 信號詞 | Danger |
| 危險性說明 | H315 : Causes skin irritation. H319 : Causes serious eye irritation. H370 : Causes damage to organs. |
| 防範說明 | P501 : Dispose of contents/ container to an approved waste disposal plant. P260 : Do not breathe dust/ fume/ gas/ mist/ vapors/ spray. P270 : Do not eat, drink or smoke when using this product. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ eye protection/ face protection. P302 + P352 : IF ON SKIN: Wash with plenty of water. P337 + P313 : If eye irritation persists: Get medical advice/ attention. P305 + P351 + P338 : IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P308 + P311 : IF exposed or concerned: Call a POISON CENTER/doctor. P362 + P364 : Take off contaminated clothing and wash it before reuse. P332 + P313 : If skin irritation occurs: Get medical advice/ attention. P405 : Store locked up. |
相關法規
| RTECS # | KK7450000 |
運輸資料
| HS編碼* | 2933.99-000 |
Application
Dipyridamole: A Phosphodiesterase (PDE) Inhibitor
Dipyridamole is a phosphodiesterase (PDE) inhibitor.1,2) PDE is a enzyme known to break a phosphodiester bond and degrade cyclic nucleotides. Dipyridamole increases the intracellular levels of cyclic adenosine monophosphate (cAMP) [A2381] and cyclic guanine monophosphate (cGMP) by preventing their conversion to their monophosphates AMP [A0158] and GMP, respectively. Therefore, dipyridamole prevents platelet aggregation by increasing cAMP and cGMP. Furthermore, dipyridamole inhibits the uptake of adenosine into platelets, endothelial cells and erythrocytes. This inhibition results in an increase in local concentrations of adenosine thereby stimulating platelet adenylate cyclase and increasing platelet cAMP levels. In clinical, dipyridamole is used as an antithrombotic agent with antiplatelet activity. Recently, it has been suggested that dipyridamole has beneficial effects for the treatment of COVID-19.3,4) (The product is for research purpose only.)
References
- 1) Dipyridamole (a review)
- 2) Translational therapeutics of dipyridamole (a review)
- 3) Molecular docking reveals the potential of aliskiren, dipyridamole, mopidamol, rosuvastatin, rolitetracycline and metamizole to inhibit COVID-19 virus main protease
- 4) Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19
考研文獻
TCIMail
產品文件 （部分產品的分析圖譜無法提供，敬請諒解。）
SDS
請選擇語言。
請求的SDS不可用。
如需更多幫助，請聯繫我們 。
產品規格
檢驗報告(CoA)及其他文檔
請輸入批號
輸入的批號不正確
示例 CoA
可下載CoA示例。注：該示例可能非最新批次的CoA。
目前沒有該產品的 CoA 示例。
分析圖譜
請輸入批號
輸入的批號不正確
很抱歉，您搜索的分析圖譜無法提供。